BGB-16673 + glofitamab

BGB-16673 + glofitamab is an investigational combination therapy comprised of BGB-16673, an orally available, chimeric degrader targeting Bruton's tyrosine kinase (BTK), and glofitamab, a bispecific monoclonal antibody targeting CD20 and CD3. BGB-16673 works by promoting proteasomal degradation of both wild-type and mutant forms of BTK, disrupting B-cell receptor signal transduction, overcoming resistance often seen with BTK inhibitors and leading to anti-cancer effects in B-cell malignancies[1][2][3][5]. Glofitamab is designed to induce T-cell-mediated cytotoxicity against malignant B-cells by engaging CD3 on T-cells and CD20 on B-cells. This combination is under early-phase clinical investigation for relapsed/refractory B-cell malignancies such as chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and indolent non-Hodgkin lymphomas. Both agents act via different mechanisms: BGB-16673 depletes BTK in malignant cells, while glofitamab redirects T-cells to drive direct killing of B-cells.